Primary Structure of Peptides Used to Immunize HLA A2.1 Transgenic Mice
| Lipid Molecule(s) . | Adaptor Sequence . | Epitope Sequence . | Carboxyl Terminus . |
|---|---|---|---|
| 0 | -K-S-S- | -N-L-V-P-M-V-A-T-V- | OH |
| 1 Palmitic acid | -K-S-S- | -N-L-V-P-M-V-A-T-V- | OH |
| 2 Palmitic acid | -K-S-S- | -N-L-V-P-M-V-A-T-V- | OH |
| Lipid Molecule(s) . | Adaptor Sequence . | Epitope Sequence . | Carboxyl Terminus . |
|---|---|---|---|
| 0 | -K-S-S- | -N-L-V-P-M-V-A-T-V- | OH |
| 1 Palmitic acid | -K-S-S- | -N-L-V-P-M-V-A-T-V- | OH |
| 2 Palmitic acid | -K-S-S- | -N-L-V-P-M-V-A-T-V- | OH |
Peptides were synthesized on the ABI 432 (Applied Biosystems) and purified and analyzed as described in the legend to Table 1. Palmitic acid (Aldrich) was dissolved in dimethylformamide, and automatically coupled to the amino terminal lysine. The amino terminal lysine of the monolipidated form of the peptide was protected by two protecting groups, Fmoc and Boc. Only the Fmoc is cleaved during synthesis to allow for a single lipid moiety to be added. For the dilipidated form, a double Fmoc protected form of lysine was used, therefore allowing for two lipid moieties to be added. Refer to Materials and Methods for further details of the synthesis of lipidated peptides.